Hana B. Moran
Nessuna posizione attualmente
Profilo
Hana B.
Moran worked as a Principal at Scios, Athena Biotechnologies, Hana Biosciences, Intarcia Therapeutics, and Sangstat Pharmaceuticals Corp.
She also worked as Vice President-Regulatory Affairs & Compliance at Galena Biopharma, Inc. and as VP-Regulatory Affairs & Quality Assurance at Talon Therapeutics, Inc. Moran holds a doctorate degree from the Weizmann Institute of Science and a graduate degree from the Slovak University of Technology.
Precedenti posizioni note di Hana B. Moran
| Società | Posizione | Fine |
|---|---|---|
Athena Biotechnologies, Inc.
 Athena Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Athena Biotechnologies, Inc. develops biotechnology products. The firm offers services to the pharmaceutical and agricultural industries. Athena Biotechnologies was founded by Barry L. Marrs in January 2005 and is headquartered in Newark, DE. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - |
| Sangstat Pharmaceuticals Corp. | Corporate Officer/Principal | - |
| Hana Biosciences, Inc. /Old/ | Corporate Officer/Principal | - |
Formazione di Hana B. Moran
| Weizmann Institute of Science | Doctorate Degree |
| Slovak University of Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 7 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
Galena Biopharma, Inc.
 Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
Athena Biotechnologies, Inc.
Athena Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Athena Biotechnologies, Inc. develops biotechnology products. The firm offers services to the pharmaceutical and agricultural industries. Athena Biotechnologies was founded by Barry L. Marrs in January 2005 and is headquartered in Newark, DE. | Health Technology |
| Hana Biosciences, Inc. /Old/ | Health Technology |
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Sangstat Pharmaceuticals Corp. |
- Borsa valori
- Insiders
- Hana B. Moran
